Daxor unveils new fda-cleared bva analyzer amid strong market demand and pivotal clinical data at hfsa

Three studies validate bva-guided care significantly cuts hospital readmissions and boosts survival in high-cost heart failure segments oak ridge, tn, sept. 30, 2025 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the heart failure society of america (hfsa) annual scientific meeting.
DXR Ratings Summary
DXR Quant Ranking